AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 2 - (NewsRx.com & NewsRx.net) -- Novavax, Inc., (NVAX) announced that the U.S. Food and Drug Administration (FDA) has accepted its new drug application (NDA) for Estrasorb for review.
The company resubmitted its NDA for Estrasorb on September 9, 2002, less than 5 months after voluntarily withdrawing the filing in April 2002 after the FDA requested additional information with respect to the company's initial NDA filing. Estrasorb, an estradiol topical emulsion, is an estrogen-only lotion-like formulation being developed for short-term use in the reduction of vasomotor symptoms, such as hot flushes, in menopausal women.
"We are very pleased that our NDA resubmission has been accepted for review by the FDA and we look forward to working closely with the agency ...
Source: HighBeam Research, Estrasorb accepted for review by the FDA.(Novavax Inc. )(Brief...